(Q38349768)

2 September 2017

title

Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice (English)

1 reference

2 September 2017

0 references

Cincotta AH

1

1 reference

2 September 2017

Tozzo E

series ordinal

2

1 reference

2 September 2017

Scislowski PW

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

2 September 2017

1 reference

2 September 2017

volume

61

1 reference

2 September 2017

issue

10

1 reference

2 September 2017

page(s)

951-956

1 reference

Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Bromocriptine alters hormone rhythms and lipid metabolism in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Effects of limited food intake on the obese-hyperglycemic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Fatty acid synthesis in liver and adipose tissue of normal and genetically obese (ob/ob) mice during the 24-hour cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

Effects of the obese gene product on body weight regulation in ob/ob mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900599-7

10.1016/S0024-3205(97)00599-7

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference